CYP2D6 is expressed in tissues including the liver, kidney, placenta, brain, breast, lungs, and small intestine. It is expressed at a low level in human liver, accounting for only approximately 3% of total CYP450 protein. In the small intestine, CYP2D6 is expressed in the duodenum and jejunum and not in the ileum and colon.
Approximately 7–10% of the Caucasian population shows an inherited deficiency in this enzyme due to the presence of one or several mutant alleles at the CYP2D6 gene locus.
| Potent Inhibitors |
Strength |
Dosage |
Verified in Humans |
| 9-(1,3-benzodioxol-5-yl)-1-pyrrolidin-1-ylnon-8-en-1-one (in black pepper) |
>50 % inhibition |
10 mM[10] |
? |
| Alpha-bisabolol (from German chamomile) |
50 % inhibition |
IC50 = 2.18 microM[12] |
? |
| Andrographis paniculata |
>70% inhibition[11] |
IC50 86 μg/ml |
? |
| Benzyl isothiocyanate [6] |
? |
? |
? |
| Berberine (in goldenseal)[1][15] |
Potent inhibition (900% increase in substrates[15]) |
300 mg for 2 weeks[15] |
Yes[15] |
| Black Cumin seed (Nigella sativa) |
99% inhibition |
2.5 g twice daily for seven days |
Yes[8] |
| Black pepper extract |
72.8% inhibition[11] |
? |
? |
| Cannabidiol (from cannabis) |
? |
? |
? |
| Catharanthus roseus extract |
50% inhibition |
IC50=11 microg/ml[11] |
? |
| Chamazulene (from German chamomile) |
50 % inhibition |
IC50 = 1.06 microM[12] |
? |
| Cinnamomum burmanni |
>70% inhibition[11] |
IC50 1203 μg/ml |
? |
| Dihydrotanshinone |
50% Inhibition |
IC50=35.4 μM[9] |
? |
| Goldenseal extract[1][4] |
50% Inhibition |
1070 mg, 3 times daily |
Yes |
| Licorice root extract |
70% inhibition[11] |
IC50= 515 μM/ml |
? |
| Pipercyclobutanamide A (in black pepper) |
>50 % inhibition |
10 mM[10] |
? |
| Pomegranate extract (Punica granatum) |
>70% inhibition[11] |
IC50 32 μg/ml |
? |
| Pummelo |
? |
? |
? |
| Resveratrol |
A 70% increase in substrates |
1 gram daily for 4 weeks |
Yes[14] |
| Rheum palmatum |
>70% inhibition[11] |
IC50 385 μg/ml |
? |
| Santalum album |
>70% inhibition[11] |
IC50 886 μg/ml |
? |
| Star fruit juice |
? |
? |
? |
| Syzygium aromaticum |
>70% inhibition[11] |
IC50 249 μg/ml |
? |
| Tinospora crispa |
>70% inhibition[11] |
IC50 488 μg/ml |
? |
| Zingiber aromaticum |
>70% inhibition[11] |
IC50 693 μg/ml |
? |
| Moderate Inhibitors |
Strength |
Dosage |
Verified in in Humans |
| Alpha-asarone (found in Calamus EO) [2] |
? |
IC50 = 55.2 μg/ml |
? |
| Calamus EO [2] |
? |
1-3 drops (unverified) |
? |
| Pi. cubeba |
? |
? |
? |
| Quercetin |
? |
? |
? |
| Zingiber aromaticum |
? |
? |
? |
| Weak Inhibitors |
Strength |
Dosage |
Verified in in Humans |
| Black cohosh [4] |
Weak inhibition |
? |
Yes |
| Black cohosh extract [1] |
No effect |
40 mg, twice daily |
Yes |
| Capsaicin (found in cayenne pepper, habanero peppers, etc.) |
? |
? |
? |
| Cayenne pepper |
? |
? |
? |
| Cryptotanshinone |
? |
? |
? |
| Curcuma heyneana |
? |
? |
? |
| Curcumin |
? |
? |
? |
| German chamomile EO |
? |
? |
? |
| Habanero pepper |
? |
? |
? |
| Hydrastine (in goldenseal)[1] |
50% Inhibition |
(IC50 = 350 μM |
? |
| Safrole |
? |
? |
? |
| Sage [5] |
? |
? |
? |
| Tanshinone I |
? |
? |
? |
| Turmeric |
? |
? |
? |
| In Vitro Inhibitors Inactive in Humans |
Strength |
Dosage |
Verified in in Humans |
| Echinacea purpurea extract [1] |
Inactive |
267 mg, three times daily |
Yes |
| Milk Thistle extract [1] |
Inactive |
300 mg, three times daily |
Yes |
| Ginkgo biloba [4] |
Inactive |
? |
Yes |
| Kava [4] |
Inactive |
? |
Yes |
| Saint John’s Wort extract [1] |
Inactive |
300 mg, three times daily |
Yes |
| Valerian Root [4] |
Inactive |
? |
Yes |
| White grapefruit juice [7] |
Inactive |
3 cups |
Yes |
| In Vitro Inhibitors Inactive in Rats |
Strength |
Dosage |
Verified in Humans |
| Chamomile [13] |
Inactive |
? |
? |
| Inducers |
Strength |
Dosage |
Verified in Humans |
| Valerian root (inhibits then induces) |
? |
? |
? |
| Valerian root EO |
? |
2-5 drops (unverified) |
? |
Bibliography
1. Clinical assessment of CYP2D6-mediated herb-drug interactions in humans: effects of milk thistle, black cohosh, goldenseal, kava kava, St. John's wort, and Echinacea.
Gurley BJ, Swain A, Hubbard MA, Williams DK, Barone G, Hartsfield F, Tong Y, Carrier DJ, Cheboyina S, Battu SK; PubMed PMID
18214849
2. Fitoterapia. 2011 Apr;82(3):369-74. doi: 10.1016/j.fitote.2010.11.009. Epub 2010 Nov 6;
Metabolism mediated interaction of α-asarone and Acorus calamus with CYP3A4 and CYP2D6; Pandit S, Mukherjee PK, Ponnusankar S, Venkatesh M, Srikanth N; School of Natural Product Studies, Department of Pharmaceutical Technology, Jadavpur University, Kolkata, India; PubMed PMID
21062640
3.
Clin Pharmacol Ther. 2002 Sep;72(3):276-87.
Cytochrome P450 phenotypic ratios for predicting herb-drug interactions in humans. Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Cui Y, Ang CY.; Department of Pharmaceutical Sciences, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, 72205, USA; PubMed PMID:
12235448
4. Clin Pharmacol Ther. 2005 May;77(5):415-26;
In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4/5 phenotypes; Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Khan IA, Shah A; Department of Pharmaceutical Sciences, College of Pharmacy, University of Arkansas for Medical Sciences, 4301 W Markham St, Slot 522, Little Rock, AR 72205, USA; PubMed PMID:
15900287
5. Hellum BH, Nilsen OG;
The in vitro inhibitory potential of trade herbal products on human CYP2D6-mediated metabolism and the influence of ethanol; Basic Clin Pharmacol Toxicol. 2007 Nov;101(5):350-8; Department of Cancer Research and Molecular Medicine, Faculty of Medicine, Norwegian University of Science and Technology, Trondheim, Norway.
6. Shufeng Zhou, Hwee-Ling Koh, Yihuai Gao,
Zhi-yuan Gong, Edmund Jon Deoon Lee;
Herbal bioactivation: The good, the bad and the ugly; Life Sciences 74 (2004) 935 – 968; April 2003; DOI:10.1016/j.lfs.2003.09.035 (
Download Attached PDF Document)
7. Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression.
Lown KS, Bailey DG, Fontana RJ, Janardan SK, Adair CH, Fortlage LA, Brown MB, Guo W, Watkins PB. PubMed PMID:
9153299
8. Effect of black seed on dextromethorphan O- and N-demethylation in human liver microsomes and healthy human subjects.
Al-Jenoobi FI, Al-Thukair AA, Abbas FA, Ansari MJ, Alkharfy KM, Al-Mohizea AM, Al-Suwayeh SA, Jamil S. PubMed PMID:
20201775
9. Molecular docking and enzyme kinetic studies of dihydrotanshinone on metabolism of a model CYP2D6 probe substrate in human liver microsomes.
Zhou X, Wang Y, Or PM, Wan DC, Kwan YW, Yeung JH. PubMed PMID:
22541637
10. Mechanism-based inhibition of human liver microsomal cytochrome P450 2D6 (CYP2D6) by alkamides of Piper nigrum.
Subehan, Usia T, Kadota S, Tezuka Y. PubMed PMID:
16808005
11. CYP3A4 and CYP2D6 inhibitory activities of Indonesian medicinal plants.
Usia T, Iwata H, Hiratsuka A, Watabe T, Kadota S, Tezuka Y. PubMed PMID:
16360935
12. Inhibitory effects of the essential oil of chamomile (Matricaria recutita L.) and its major constituents on human cytochrome P450 enzymes.
Ganzera M, Schneider P, Stuppner H. PubMed PMID:
16137701
13. Effect of herbal teas on hepatic drug metabolizing enzymes in rats.
Maliakal PP, Wanwimolruk S. PubMed PMID:
11697539
14.
Resveratrol Modulates Drug- and Carcinogen-Metabolizing Enzymes in a Healthy Volunteer Study H-H. Sherry Chow, Linda L. Garland, Chiu-Hsieh Hsu, Donna R. Vining, Wade M. Chew, Jessica A. Miller, Marjorie Perloff, James A. Crowell and David S. Alberts; DOI: 10.1158/1940-6207.CAPR-09-0155 Published September 2010;
PubMed PMCID: PMC2933312; NIHMSID: NIHMS207754
15. Repeated administration of berberine inhibits cytochromes P450 in humans
Ying Guo, Yao Chen, Zhi-rong Tan, Curtis D. Klaassen, Hong-hao Zhou; Published online 2011 Aug 26.; Eur J Clin Pharmacol. 2012 Feb; 68(2): 213–217.; doi: 10.1007/s00228-011-1108-2; NIHMSID: NIHMS583946;
PMCID: PMC4898966